Flyvbjerg A
Medical Department M (Diabetes and Endocrinology), Institute of Experimental Clinical Research, University of Aarhus, Aarhus Community Hospital, Denmark.
Diabetologia. 2000 Oct;43(10):1205-23. doi: 10.1007/s001250051515.
The development of diabetic nephropathy in patients with Type I (insulin-dependent) and Type II (non-insulin-dependent) diabetes mellitus is still a huge clinical problem associated with increased morbidity and mortality. The mechanisms underlying the development of diabetic kidney disease are extremely complex and yet not completely understood. Among many potential pathogenic mechanisms responsible for the development of diabetic kidney disease, various growth factors have been suggested to be important players. In particular, growth hormone (GH)/insulin-like growth factors (IGFs), transforming growth factor beta (TGF-beta), vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) have measurable effects on the development of experimental diabetic kidney disease through complex intra-renal systems. Recent findings that these growth factors might initiate the early diabetic renal changes have provided insight into processes that might be relevant for future development of new drugs useful in the treatment of diabetic kidney disease. As will appear from the present review, enhanced understanding of the cellular mechanisms responsible for the development of diabetic kidney disease has already allowed the design of specific antagonists of pathophysiologically increased growth factors. Recent studies have shown that treating experimental diabetic models with such antagonists is followed by renoprotection.
1型(胰岛素依赖型)和2型(非胰岛素依赖型)糖尿病患者糖尿病肾病的发展仍然是一个与发病率和死亡率增加相关的重大临床问题。糖尿病肾病发展的潜在机制极其复杂,尚未完全明确。在导致糖尿病肾病发展的众多潜在致病机制中,各种生长因子被认为起着重要作用。特别是,生长激素(GH)/胰岛素样生长因子(IGF)、转化生长因子β(TGF-β)、血管内皮生长因子(VEGF)和表皮生长因子(EGF)通过复杂的肾内系统对实验性糖尿病肾病的发展具有可测量的影响。这些生长因子可能引发早期糖尿病肾脏改变的最新发现,为未来开发治疗糖尿病肾病的新药相关过程提供了见解。正如本综述将显示的那样,对导致糖尿病肾病发展的细胞机制的深入了解已经使得能够设计出针对病理生理上增加的生长因子的特异性拮抗剂。最近的研究表明,用这种拮抗剂治疗实验性糖尿病模型后可实现肾脏保护。